Stemedica Cell Technologies’ Subsidiary

Starts Stem Cell TrialsBy Stemedica

A respected biotechnology company, Stemedica Cell Technologies, Inc., remains at the forefront of regenerative medicine through innovations in stem cells and biological compounds. Additionally, Stemedica Cell Technologies produces some of these advancements through its recently formed cardiology subsidiary named CardioCell LLC.

Introduction

n February 2014, CardioCell announced that the Company will begin a Phase IIa clinical trial in the United States and Phase III clinical trial in Kazakhstan for the treatment of acute myocardial infarction using Stemedica’s allogeneic ischemic tolerant mesenchymal stem cells. The U.S. based trial will occur at the University of California San Diego, and at Mercy Gilbert Medical Center and Chandler Regional Medical Center in Arizona. The researchers, who are currently recruiting participants, will post the latest information about the trials at Clinicaltrials.gov. More information can also be found at www.Stemedica.com

About CardioCell